regulatory review
CHMP Recommends Five New Drugs and Reviews Eli Lilly’s Kisunla
CHMP; EMA; new drug approvals; Eli Lilly; Kisunla; biosimilars; hyperphosphatemia; myopia; March 2025; regulatory review
FDA Declines Approval for J&J’s Subcutaneous Rybrevant and AstraZeneca’s Full Approval Bid for Andexxa
FDA, J&J, Rybrevant, AstraZeneca, Andexxa, regulatory review, pharmaceuticals